drugset / Trial / NCT04550325
Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia
Timeline
- Start
- 2020-08-05
- Primary completion
- 2020-11-26
- Completion
- 2020-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Kamada Anti-SARS-CoV-2 | Protein / enzyme biologic | 4 g | Intravenous |